Emerging Systemic Therapy: JAK Inhibitors |
eMediNexus Coverage from: 
Emerging Systemic Therapy: JAK Inhibitors
Dr Yashpal Manchanda, New Delhi,  21 January 2019
Coronavirus Live Count Map India

remove_red_eye 910 Views
COVID-19 Vaccine Updates

Coronavirus Protocols


0 Read Comments                

Janus kinase inhibitors also known as jakinibs, inhibit the kinase component of JAKs, thereby preventing them from phosphorylating and stopping the transduction of intercellular signalling.First-generation jakinibs, which include the drugs tofacitinib and ruxolitinib inhibit multiple JAKs.Second-generation jakinibs are still under investigation and more selective target only one JAK isoform, thereby inhibiting a narrower range of cytokines.The dermatological uses of jakinibs include atopic derma...
To read the complete article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now